Basel Medical Group Ltd (the "Company") is filing this Amendment No. 1 ("Amendment") to its Annual Report on Form 20-F for the fiscal year ended June 30, 2025, as initially filed with the U.S. Securities and Exchange Commission (the "SEC") on November 18, 2025 (the "Initial Filing"), for the purpose of amending and restating the sections "Item 3. Key Information-D. Risk Factors", "Item 4. Information on the Company-A. History and Development of the Company", "Item 4. Information on the Company-B. Business Overview", "Item 4. Information on the Company-C. Organizational Structure", "Item 5. Operating and Financial Review and Prospects", "Item 7. Major Shareholders and Related Party Transactions-B. Related Party Transactions", "Item 16C. Principal Accountant Fees and Services", to refile a new report of the independent registered public accounting firm NLA DFK Assurance PAC to its audited consolidated financial statements for the years ended June 30, 2024 and 2025, and to amend and restate its audited consolidated financial statements for the years ended June 30, 2024 and 2025 and the notes thereto.
As required by Rule 12b-15 of the Securities and Exchange Act of 1934, as amended, the Company is filing or furnishing the certifications required under Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 as exhibits to this Amendment, and is also refiling its exhibit 8.1 to amend and restate its list of subsidiaries as of March 13, 2026.